Neurological conditions that mimic Guillain-Barré Syndrome and how to differentiate them
GBS, a neurological condition triggered by an overactive immune system often after viral or bacterial infections, has been detected in Pune. Early sym ...
Hansa Biopharma sees 2025 growth through expanded IDEFIRIX adoption and new market reimbursements
Management projected strong growth for 2025, driven by expanded reimbursement in key European markets such as Spain and Italy and the expected completion of the post-approval efficacy study (PAES).
STAT11h
Previewing Immunovant’s myasthenia gravis study readout — with all its quirky nuance
It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.
Why is identifying Guillain Barre Syndrome (GBS) difficult?
Guillain-Barré Syndrome (GBS) poses a diagnostic challenge due to its misleading symptoms, the lack of a definitive test, and ...
Country Star Details 60-Pound Weight Loss After Near-Fatal Heart Attack
Country-rap star Colt Ford got candid with People about his dramatic 60-pound weight loss following a near-fatal heart attack ...
DVLA lists every condition you need to declare or face £1,000 fine
It warns: "You need to tell DVLA about some medical conditions as they can affect your driving. You can be fined up to £1,000 ...
Immunovant’s Promising Pipeline: Strategic Advances in FcRn Inhibitors and Market Expansion
Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Immunovant (IMVT – Research Report), retaining the price target of ...
PharmiWeb6d
RYSTIGGO® (rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods
UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...